Last updated: February 23, 2026
What Is NDC 31722-0868?
NDC 31722-0868 refers to Tymlos (abaloparatide) injection, indicated for postmenopausal women with osteoporosis at high risk for fracture.
Market Overview
Target Population
- Postmenopausal women with osteoporosis at high fracture risk
- Estimated affected population in the U.S.: approximately 10 million women
- Annual new cases: ~1.2 million women diagnosed with osteoporosis yearly
Competitive Landscape
- Key competitors: Forteo (teriparatide), Evenity (romosozumab)
- Market share focus on anabolic agents: Tymlos, Forteo, Evenity
- U.S. sales (2022): approximately $150 million, with potential for growth
Market Drivers
- Rising osteoporosis prevalence due to aging population
- Favorable reimbursement policies for high-risk patients
- Increased prescribing as physicians seek anabolic alternatives
Market Constraints
- Preference for bisphosphonates in early treatment
- Injectable therapy adherence challenges
- Cost sensitivity among payers and patients
Pricing History and Current Pricing
Tymlos Pricing
- List price (2023): approximately $4,713 per 28-day supply (per 4 mL prefilled pen)
- Average wholesale price (AWP): consistent with list price
- Reimbursement: varies by payer, average selling prices closer to $3,500–$4,200 after discounts and rebates
Price compared to competitors
| Drug |
Indication |
List Price (approx.) |
Annual Cost |
| Tymlos |
Osteoporosis in postmenopausal women |
$4,713/month |
$56,556/year |
| Forteo |
Similar indication |
$4,200/month |
$50,400/year |
| Evenity |
Severe osteoporosis, high fracture risk |
$6,000/month |
$72,000/year |
Price Projections and Market Trends
Short-term projections (next 1-2 years)
- Minor price adjustments anticipated due to inflation and market competition.
- List price likely remains in the $4,700–$5,000 range.
- Reimbursement pressures may push net prices down 5–10%.
Medium to long-term projections (3-5 years)
- New formulations or biosimilars could emerge, pressuring prices.
- Competitive entry may result in price erosion up to 15–20%.
- Market expansion driven by increased awareness and guideline endorsements.
Impact of Patent and Regulatory Changes
- Patent expiration not currently scheduled but potential biosimilar development could impact pricing.
- Any regulatory shifts favoring biosimilars could accelerate price reductions.
Pricing Strategy Considerations
- Payers may favor value-based agreements, influencing net pricing.
- Manufacturers could introduce patient assistance to offset list price impacts.
- Volume-driven discounts may become more prevalent as market expansion continues.
Summary of Revenue Potential
- Total addressable market (TAM): approximately $150–200 million/year in the U.S. alone
- Annual sales growth expectations: 5–8%, driven by increasing prescriptions
- Price elasticity suggests slight downward pressure, but premium pricing remains viable for high-value indications
Key Takeaways
- NDC 31722-0868 (Tymlos) operates in a growing osteoporosis market with competitive anabolic agents.
- Current list price is approximately $4,713 per month; actual net prices vary based on rebates and discounts.
- Market expansion and competitive pressures could reduce prices by up to 20% within five years.
- The product's revenue prospects hinge on increased adoption among high-risk populations and payer reimbursement models.
FAQs
1. What factors influence Tymlos’ pricing?
Market competition, manufacturing costs, reimbursement negotiations, and regulatory changes directly impact Tymlos pricing.
2. How does Tymlos compare to Forteo in price and efficacy?
Both are similar in price and efficacy. Tymlos has a slightly shorter administration period (2 years maximum), which can influence prescribing choices.
3. What impact could biosimilar development have?
Biosimilars could introduce options that lower prices, especially if patent barriers are circumvented.
4. How do payers affect drug price projections?
Payers negotiate rebates and discounts, influencing the net price paid by healthcare systems.
5. What is the forecast for osteoporosis drug market growth?
The market is projected to grow at 5-8% annually due to demographic trends and increased diagnosis rates.
Sources
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2020). Tymlos (abaloparatide) Prescribing Information.
- EvaluatePharma. (2022). Oral and Injectable Osteoporosis Market Outlook.
- Medicare Reimbursement Data. (2022). 2022 Reimbursement Rates for Injectable Osteoporosis Drugs.
- Industry Reports. (2023). Biosimilars Impact on High-Value Drugs.
